PONVORY® (ponesimod) helps address unmet needs relapsing multiple sclerosis (RMS)[^1][^2][^3] [^1]: European Medicines Agency. Ponesimod Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines Last accessed: November 2021. [^2]: Mortensen GL, et al. Patient Preference and Adherence. 2017;11:1789–1796. [^3]: Comi G, et al. Lancet. 2017;389(10076):1347-1356.

You can watch the recording of the PONVORY^® product theatre presentation by Prof. Dr. Ralf Gold below:

Video Not Published

An expert in multiple sclerosis (MS)

Prof. Dr. Ralf Gold - Director Neurological Clinic, St. Josef Hospital, Bochum, Germany

Over the last 24 years, Prof. Gold has led numerous MS clinical research teams across Germany. His research focusses on the clinical care of MS patients, involving clinical trials as well as studies to improve specific immunotherapies for MS. He has received several scientific prizes for his work including the Pette Prize of the DGN, the Mertens Prize, and the Sobek Research Prize 2011.

To find out more about PONVORY^®

MS=multiple sclerosis; RMS=relapsing multiple sclerosis.

You can watch the recording of the PONVORY® product theatre presentation by Prof. Dr. Ralf Gold below:

An expert in multiple sclerosis (MS)

To find out more about PONVORY®

You can watch the recording of the PONVORY^® product theatre presentation by Prof. Dr. Ralf Gold below:

To find out more about PONVORY^®